Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model.
Appl Microbiol Biotechnol
; 100(16): 7051-60, 2016 Aug.
Article
em En
| MEDLINE
| ID: mdl-26960322
ABSTRACT
Leishmaniasis is a parasitic disease transmitted through the bite of an infected phlebotomine sand fly and caused by protozoan parasites of the genus Leishmania. There is no available vaccine for leishmaniasis in human, and the current chemotherapy approaches are hampered by different clinical problems. Most of available drugs are confined to a limited number of toxic chemical compounds, which some parasite strains have evolved drug resistance against. Hence, drug discovery and production of a new anti leishmanial compound is essential. One promising strategy is using the nanoparticle delivery systems with the aim of accelerating the efficacy of the available treatments. In the present study, paromomycin sulfate (PM) was formulated in solid lipid nanoparticles (SLN) and the in vivo efficacy was investigated against Leishmania tropica in BALB/c mice model. To do so, the increase in footpad thickness was measured and real-time PCR was performed to quantify the parasite load after infectious challenge. The level of nitric oxide and cytokines including interleukin-4 (IL-4) and gamma interferon (IFN -γ) were assessed. Altogether, the results show that PM loaded into SLN is significantly more effective than PM alone in inhibiting the parasite propagation and switching towards Th1 response.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Leishmania tropica
/
Portadores de Fármacos
/
Paromomicina
/
Leishmaniose
/
Nanopartículas
/
Antiprotozoários
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Appl Microbiol Biotechnol
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Irã